PacBio and ARUP Laboratories Collaborate in a Study to Improve Rare Disease Diagnosis

Rhea-AI Summary

PacBio (NASDAQ: PACB) has partnered with ARUP Laboratories to improve the diagnostic yield for unexplained rare disease cases through whole genome HiFi sequencing. This collaboration aims to leverage PacBio's Sequel IIe system within the Utah NeoSeq Project, enhancing the detection of variants that short-read sequencing might miss. Currently, diagnostic yield stands at 30%-50%, and the study seeks to increase this by utilizing HiFi sequencing to analyze previously sequenced samples. If successful, HiFi WGS may serve as a frontline diagnostic tool for rare disorders.

Positive

• Collaboration with ARUP Laboratories to improve rare disease diagnosis.
• Utilization of the Sequel IIe system may enhance detection of variants.
• Opportunity to increase diagnostic yield beyond current 30%-50% rates.
• HiFi sequencing may lead to clinical assays for difficult-to-sequence genomic areas.

Negative

• None.

Whole genome HiFi sequencing will be used on unexplained rare disease cases to evaluate if it can identify variants not readily detectable by short-read sequencing

MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, and ARUP Laboratories announced today they are collaborating on a study intended to evaluate whether the solve rate for rare disease cases can be increased.

ARUP Laboratories has purchased a PacBio Sequel IIe system for use in the Utah NeoSeq Project. The project, launched in early 2020, leverages an accelerated sequencing and analysis pipeline intended to provide a genetic diagnosis for patients in the neonatal intensive care unit (NICU) in less than a week. By incorporating the Sequel IIe in the study, the team hopes to demonstrate the potential of long-read HiFi sequencing technology to identify variants in areas of the genome that are difficult to sequence with short-read sequencing technologies and, ultimately, increase diagnostic yield for rare disease cases.

Currently, the cause of more than half of rare disease cases worldwide remains unexplained. Using short-read whole genome sequencing (WGS), the lab’s current diagnostic yield for rare disease is about 30% to 50%. The study will explore the use of HiFi WGS, which provides more comprehensive, accurate, and high-definition coverage of hard-to-read regions in the human genome, to determine if it can identify variants, both small and structural, that were not readily detectible by short-read WGS. Additionally, ARUP Laboratories is seeking to develop clinical assays for areas that are difficult to sequence with short-read sequencing technologies, such as repeat expansions and pseudogenes.

“Our team at ARUP Laboratories knows that each sample represents a patient, and we want to do everything that we can to provide every patient who comes to us with a diagnosis,” said Hunter Best, PhD, Medical and Scientific Director of Genomics, ARUP Laboratories. “With the incorporation of HiFi WGS in the study, we believe that we will be able to obtain more insight into the samples we receive, ultimately helping our clients and their patients find answers.”

The initial phase of the study uses HiFi WGS on those samples already sequenced with short-read technology, but without a resulting diagnosis. The goal is to wrap up this phase of the project in the first quarter of 2022. Should the initial phase of the study be successful, the project will explore using HiFi WGS as a frontline diagnostic tool for rare and inherited disorders.

“PacBio continues this march of technology evolution, and we anticipate that ultimately more than half, and perhaps up to two-thirds, of unsolved rare disease cases could be explained through HiFi sequencing,” said Jonas Korlach, PhD, Chief Scientific Officer at PacBio. “We are thrilled to be collaborating with ARUP Laboratories to help them with a study designed to find answers for patients with rare diseases. We believe that high-quality WGS is the future of medicine and that this collaboration will be one of many impactful demonstrations.”

To learn more about the benefits of HiFi WGS in rare disease, visit www.pacb.com/rare-disease.

About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB), is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

About ARUP Laboratories
Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nation’s top university teaching hospitals and children’s hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®. ARUP is ISO 15189 CAP accredited.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements relating to future availability, uses, accuracy, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, the suitability or utility of such products or technologies for particular applications or projects, including in connection with the Utah NeoSeq Project, potential increases in variant detection, rare disease answers, solve rates and diagnostic yields in the Utah NeoSeq Project in particular and rare disease research in general, use of PacBio technology in the development of clinical or diagnostic assays, anticipated timing to complete the Utah NeoSeq Project, including phases thereof, the potential future use of WGS in medicine, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond PacBio’s control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in PacBio’s most recent filings with the Securities and Exchange Commission, including PacBio’s most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” PacBio undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

PacBio Contacts

Investors:
Todd Friedman
+1 (650) 521-8450
ir@pacb.com

Media:
Kathy Lynch
pr@pacb.com

ARUP Contact
Jennifer Dobner
801-718-2123
media@aruplab.com

FAQ

What is the purpose of the PacBio and ARUP Laboratories collaboration?

The collaboration aims to enhance the diagnostic yield for unexplained rare disease cases using whole genome HiFi sequencing.

How does the Sequel IIe system contribute to rare disease diagnostics?

The Sequel IIe system is expected to identify genomic variants that short-read sequencing may miss, potentially increasing diagnostic accuracy.

What is the current diagnostic yield for rare disease cases?

The current diagnostic yield for rare disease cases using short-read sequencing is approximately 30% to 50%.

When does the initial phase of the study expect to conclude?

The initial phase of the study is anticipated to conclude in the first quarter of 2022.

What are the implications if the study with HiFi sequencing is successful?

If successful, HiFi WGS may be used as a frontline diagnostic tool for rare and inherited disorders.